Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199523 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 352
- Enrollment target
NCT01199523: Completed Phase 1 study, sponsored by Astellas Pharma.
NCT01199523 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 352 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (487% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01199523, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 352 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect of repeat oral dosing of mirabegron on ECG (electrocardiogram) measurements.
Primary Outcome
QTcI is a QT interval corrected for heart rate using individual-specific correction formula
Interventions
- DRUG Placebo
- DRUG mirabegron
- DRUG moxifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
What the finished NCT01199523 record still lists
NCT01199523 is an interventional study that assigns participants to a tested intervention. The registered 352 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (487% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01199523 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01199523 about?
NCT01199523 is a clinical study titled "A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females". The objective of this study is to evaluate the effect of repeat oral dosing of mirabegron on ECG (electrocardiogram) measurements.
What is the current status of trial NCT01199523?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 352 participants. The study started on 2010-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01199523?
The interventions under investigation include: Placebo (DRUG), mirabegron (DRUG), moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT01199523?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01199523's enrollment target sits among peer trials
352 95th of 2000 higher than 1,905 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05811936 · 352 participants · NA
The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads
- NCT06258941 · 352 participants · Phase 1
Classroom Break, Cognition, and Fitness in Elementary School Children
- NCT06269081 · 352 participants · NA
Testing Two Interventions to Improve Health Outcomes and Quality of Life Among Rural Older Adults Living With HIV
- NCT06337292 · 352 participants · Phase 3
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia